|
| Study | Method | Duration | N (M : F) | Mean age | Interventions | Symptom improvement |
|
| Gao, 2003 [27] | RCT, not blinded
Comparison: individuals | 4 w | 164 (76 : 88) | 37.3 | (1) MCSP (bid)
(2) Domperidone (10 mg, tid) | (1) TER: 94.2% (98/104)
(2) TER: 78.3% (47/60) |
|
| G. Liang and Y. Liang, 2005 [28] | RCT, not blinded
Comparison: individuals | 4 w | 83 (38 : 45) | 39.6 | (1) MCSP (bid)
(2) Cisapride (10 mg, tid) | (1) TER: 90.5% (38/42)
(2) TER: 70.7% (29/41) |
|
| Huang and Yuan, 2006 [29] | RCT, not blinded
Comparison: individuals | 4 w | 137 (64 : 73) | 40.4 | (1) MCSP (bid)
(2) Domperidone (10 mg, tid) | (1) TER: 92.5% (63/69)
(2) TER: 70.6% (47/68) |
|
| Hu and Zhang, 2007 [30] | RCT, not blinded
Comparison: individuals | 12 w | 61 (16 : 45) | 39.5 | (1) MCSP (bid)
(2) Cisapride (5–10 mg, tid) | (1) TER: 67.7% (21/31)
(2) TER: 70.0% (21/30) |
|
| Zhou, 2008 [31] | RCT, not blinded
Comparison: individuals | 4 w | 80 (42 : 38) | 52.4 | (1) MCSP (bid)
(2) Cisapride (5 mg, tid), Vitamin B6 (20 mg, tid),
Oryzanol tablets (20 mg, tid) | (1) TER: 95.0% (38/40)
(2) TER : 82.5% (33/40) |
|
| Zhu, 2008 [32] | RCT, not blinded
Comparison: individuals | 4 w | 64 (28 : 36) | 36.4 | (1) MCSP (bid)
(2) Domperidone (10 mg, tid) | (1) TER: 81.3% (26/32)
(2) TER: 62.5% (20/32) |
|
| Pei and Zhao, 2009 [33] | RCT, not blinded
Comparison: individuals | 4 w | 80 (41 : 39) | 51.9 | (1) MCSP (bid),
(2) Trimebutine maleate tablets (100 mg, q.d) | (1) TER: 85.0% (34/40)
(2) TER: 82.5% (33/40) |
|
| Tan et al., 2010 [34] | RCT, not blinded
Comparison: individuals | 4 w | 71 (34 : 37) | 36.5 | (1) MCSP (bid)
(2) Flupentixol melitracen tablets (2 pills, q.d) | (1) TER: 86.1% (31/36)
(2) TER: 65.7% (23/35) |
|
| Gong, 2010 [35] | RCT, not blinded
Comparison: individuals | 4 w | 86 (30 : 56) | 36.8 | (1) MCSP (bid)
(2) Domperidone (10 mg, tid) | (1) TER: 83.7% (36/43)
(2) TER: 65.1% (29/43) |
|
| Li, 2010 [36] | RCT, not blinded
Comparison: individuals | 4 w | 60 (24 : 36) | 40.6 | (1) MCSP (bid)
(2) Cisapride (5 mg, tid) | (1) TER: 93.3% (28/30)
(2) TER: 76.7% (23/30) |
|
| Zhang, 2010 [37] | RCT, not blinded
Comparison: individuals | 3 w | 100 | N/A | (1) MCSP (bid)
(2) Cisapride (5 mg, tid) | (1) TER: 94.0% (47/50)
(2) TER: 86.0% (43/50) |
|
| Zhang, 2011 [38] | RCT, not blinded
Comparison: individuals | 4 w | 54 (23 : 31) | N/A | (1) MCSP (bid)
(2) Domperidone (10 mg, tid),
Compound Azintamide tablets (2 pills, tid) | (1) TER: 91.3% (21/23)
(2) TER: 70.9% (22/31) |
|
| Jin et al., 2012 [39] | RCT, not blinded
Comparison: individuals | 4 w | 72 (32 : 40) | 39.3 | (1) MCSP (bid)
(2) Mosapride citrate tablets (5 mg, tid) | (1) TER: 83.3% (30/36)
(2) TER: 66.7% (24/36) |
|
| Liu et al., 2005 [40] | RCT, not blinded
Comparison: individuals | 4 w | 180 (72 : 108) | 47.5 | (1) MCSP (bid), Cisapride (5 mg, tid)
(2) Cisapride (5 mg, tid) | (1) TER: 93.3% (84/90)
(2) TER: 76.7% (69/90) |
|
| Shen et al., 2005 [41] | RCT, not blinded
Comparison: individuals | 4 w | 57 (26 : 31) | 33.9 | (1) MCSP (bid), Cisapride (10 mg, tid)
(2) Cisapride (10 mg, tid) | (1) TER: 83.3% (25/30)
(2) TER: 62.9% (17/27) |
|
| Zhang and Liu, 2007 [42] | RCT, not blinded
Comparison: individuals | 4 w | 94 (38 : 56) | 56.0 | (1) MCSP (bid), Mosapride (5 mg, tid)
(2) Mosapride (5 mg, tid) | (1) TER: 93.8% (45/48)
(2) TER: 73.9% (34/46) |
|
| Liu et al., 2008 [43] | RCT, not blinded
Comparisonindividuals | 4 w | 48 (19 : 29) | 35.0 | (1) MCSP (bid), Flupentixol melitracen tablets (1 pill, q.d)
(2) Flupentixol melitracen tablets (1 pill, q.d) | (1) TER: 95.8% (23/24)
(2) TER: 87.5% (21/24) |
|
| Feng and Liu 2008 [44] | RCT, not blinded
Comparison: individuals | 4 w | 75 (33 : 42) | 36.1 | (1) MCSP (bid), Domperidone (10 mg, tid)
(2) Domperidone (10 mg, tid) | (1) TER: 89.5% (34/38)
(2) TER: 81.1% (30/37) |
|
| Pei and Zhao, 2009 [33] | RCT, not blinded
Comparison: individuals | 4 w | 80 (42 : 38) | 52.3 | (1) MCSP (bid), Trimebutine maleate tablets (100 mg, q.d)
(2) Trimebutine maleate tablets (100 mg, q.d) | (1) TER: 95.0% (38/40)
(2) TER: 82.5% (33/40) |
|
| Qiu, 2010 [45] | RCT, not blinded
Comparison: individuals | 4 w | 75 (28 : 47) | 43.5 | (1) MCSP (bid), Domperidone (10 mg, tid)
(2) Domperidone (10 mg, tid) | (1) TER: 94.7% (36/38)
(2) TER : 86.5% (32/37) |
|
| Tian, 2010 [46] | RCT, not blinded
Comparison: individuals | 4 w | 98 (43 : 55) | 40.9 | (1) MCSP (bid), Domperidone (10 mg, tid)
(2) Domperidone (10 mg, tid) | (1) TER: 87.8% (43/49)
(2) TER : 71.4% (35/49) |
|
| Fan, 2010 [47] | RCT, not blinded
Comparison: individuals | 1 m | 60 (21 : 39) | 46.5 | (1) MCSP (bid), Cisapride (5 mg, tid)
(2) Cisapride (5 mg, tid) | (1) TER : 96.7% (58/60)
(2) TER : 85.0% (51/60) |
|
